Article summary line: Several commercially available SARS-CoV-2 ELISAs show limited

specificity when applied to serum panels of African origin.

Running title: SARS-CoV-2 IgG ELISA specificity

Keywords: SARS-CoV-2, seroepidemiologic studies, immunoglobulin G, Enzyme-Linked

Immunosorbent Assay, specificity, Africa

Title:

Limited specificity of commercially available SARS-CoV-2 IgG ELISAs in serum

samples of African origin

Authors:

Petra Emmerich, Carolin Murawski, Ronald von Possel, Lisa Oestereich, Sophie Duraffour,

Meike Pahlmann, Nicole Struck, Daniel Eibach, Ralf Krumkamp, John Amuasi, Oumou

Maiga-Ascofare, Raphael Rakotozandrindrainy, Danny Asogun, Yemisi Ighodalo, Jürgen

May, Egbert Tannich, Christina Deschermeier

Affiliations:

Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany (P. Emmerich, C.

Murawski, R. von Possel, L. Oestereich, S. Duraffour, M. Pahlmann, N. Struck, D. Eibach, R.

Krumkamp, J. May, E. Tannich, C. Deschermeier)

University of Rostock, Rostock, Germany (P. Emmerich)

German Center for Infection Research (DZIF), Hamburg, Germany (L. Oestereich, S.

Duraffour, M. Pahlmann, N. Struck, D. Eibach, R. Krumkamp)

Kumasi Centre for Collaborative Research in Tropical Medicine, Kumasi, Ghana (J. Amuasi,

O. Maiga-Ascofare)

University of Antananarivo, Antananarivo, Madagascar (R. Rakotozandrindrainy)

Irrua Specialist Teaching Hospital, Irrua, Nigeria (D. Asogun, Y. Ighodalo)

National Reference Centre for Tropical Pathogens, Hamburg, Germany (E. Tannich)

Corresponding author: Christina Deschermeier

Mailing address: Bernhard Nocht Institute for Tropical Medicine, Bernhard-Nocht-Str. 74,

20359 Hamburg

Email address: descherm@bnitm.de

Phone number: +49 (40) 42818-438

ORCiD ID: 0000-0002-8309-7877

ABSTRACT

Specific serological tests are mandatory for reliable SARS-CoV-2 seroprevalence studies but assay specificity may vary considerably between populations due to interference of immune responses to other pathogens. Here, we assess the false positive rates obtained with four commercially available IgG ELISAs in serum panels originating from three different African countries.

By August 16th 2020, 945,165 laboratory-confirmed SARS-CoV-2 infections and 18,476 deaths caused by COVID-19 have been reported from the WHO Africa region (*1*). Currently, community transmission is observed in 33 African countries including Tanzania, Ghana, Madagascar, Nigeria, Kenya, and South Sudan; in 14 other African countries (*e.g.* Uganda, Burundi, Rwanda) clusters of cases or sporadic cases have been described (*1*). To correctly determine the actual exposure of the population to SARS-CoV-2 and to draw reliable conclusions on morbidity and case fatality rates, highly sensitive and specific serological tests are mandatory.

Up to now, a plethora of serological tests for detection of anti-SARS-Cov-2 antibodies has been developed and commercialized (*2, 3*). Although performance data for several of these assays have been rapidly communicated by different laboratories (*4-8*), to our knowledge no reports are available yet on the applicability of these tests on African serum panels. Here, assay specificity may be challenged by previous or current infections with other pathogens; in particular, hypergammaglobulinemia induced by *Plasmodium* infection may cause false positive results in serological tests (*9, 10*).

THE STUDY

To assess the specificities of commercially available SARS-CoV-2 IgG ELISA tests in serum panels of different origin*, a priori* SARS-CoV-2 IgG negative serum panels (**Appendix Table 1**) collected before 2019 in African countries (Ghana: n=79, Madagascar: n=79, Nigeria: n=40, comprising samples from both febrile patients and symptom-free donors), South

America (Colombia: n=40, symptom-free donors), Asia (Lao PDR: n=20, symptom-free

donors), and Europe (Germany: n=75, symptom-free donors) were analyzed with the

Euroimmun Anti-SARS-CoV-2-NCP IgG ELISA (Euroimmun, Lübeck, Germany), the

Euroimmun Anti-SARS-CoV-2 IgG ELISA (Euroimmun, Lübeck, Germany), the EDI^TM Novel

Coronavirus COVID-19 IgG ELISA (Epitope Diagnostics, San Diego, US), and the Mikrogen

*recom*Well SARS-CoV-2 IgG ELISA (Mikrogen, Neuried, Germany) (**Appendix Table 2**).

Assays were performed and evaluated according to the manufacturers' instructions. To

quantify variation of index values determined on different days/plates (inter-assay/inter-lot

variation), two sera from German patients with a previous PCR-confirmed SARS-CoV-2

infection which were collected on day 19 post onset of symptoms and one commercially

available human negative control serum (Merck Millipore) were included in each test

run/plate. In addition, subsets of serum panels were assayed using the Wantai SARS-CoV-2

Ab ELISA (Wantai, Beijing, China) detecting total anti-SARS-CoV-2 Ig (**Appendix Table 2**).

BNITM in-house SARS-CoV-2 IgG indirect immunofluorescence testing (IIFT) was performed

as described previously (*11*).

While IgG ELISA specificities where good to excellent for pre-COVID-19 serum panels

originating from Colombia, Lao PDR, Madagascar, and Germany, increased false positive

rates were observed in *a priori* SARS-CoV-2 IgG negative sera from Ghana and Nigeria

(**Figure 1, Table 1**). False positive rates were comparable in serum samples originating from

febrile vs. asymptomatic donors from Ghana; no immediately apparent correlation of false

positive ELISA results with *P. falciparum* parasitemia was observed (**Appendix Table 3**).

Nevertheless, a sound statistical analysis of possible correlations with the donors' health

status would require larger subgroups/sample numbers than were available for the current

study.

In contrast to the four indirect IgG ELISA tests evaluated in this study, the Wantai SARS-

CoV-2 Ab ELISA, detecting total antibodies employing a sandwich antigen procedure,

showed a high specificity when applied to a subset of sera from Ghana, Madagascar, and

Nigeria (**Appendix Figure 1**). Further testing with this assay was not possible due to the

large sample volume needed per well (100 µl of undiluted sample) and scarcity of stocked

pre-2019 sera. No SARS-CoV-2-specific fluorescence pattern could be observed in any of

the African samples by BNITM in-house SARS-CoV-2 IgG IIFT; non-specific staining was

observed in low dilutions of 20/79 (25.3%), 6/79 (7.6%), and 7/40 (17.5%) serum samples

from Ghana, Madagascar, and Nigeria, respectively.

While the index values obtained with the Euroimmun SARS-CoV-2-NCP IgG ELISA and the

EDI^{TM} Novel Coronavirus COVID-19 IgG ELISA, both employing recombinant SARS-CoV-2

nucleoprotein as antigen, showed a clear correlation (**Table 2, Figure 2A, 2C, 2E),** only few

serum samples were concordantly classified as positive by the nucleoprotein-based

Euroimmun SARS-CoV-2-NCP IgG ELISA and the spike-based Euroimmun Anti-SARS-CoV-

2 IgG ELISA (**Table 2, Figure 2B, 2D, 2F)**. Thus, testing specificity can be increased by

combination of two serological tests featuring different antigens (spike and nucleoprotein).

CONCLUSIONS

In accordance with evaluation studies recently published by other authors (*4-6, 8*), the

commercially available SARS-CoV-2 IgG ELISAs displayed a good to excellent specificity

when applied to serum panels originating from European or US donors. In contrast,

significantly increased false positive rates were observed in African pre-COVID-19 serum

panels originating from countries with a high malaria burden (Ghana and Nigeria (*12*)),

calling into question the eligibility of these assays for seroprevalence studies in these

regions. Therefore, the following recommendations should be considered when planning and

performing SARS-CoV-2 seroprevalence studies (not only) in Africa: 1) Prior to performance

of seroprevalence studies, carefully assess background/false positive signals obtained with

the chosen serological test(s) in the target population (using *a priori* SARS-CoV-2 IgG

negative serum samples which were stocked before 2019). Under certain circumstances,

adjustment of the assay cut-off originally proposed by the manufacturer may suffice to

improve/restore test specificity, but this may compromise assay sensitivity. 2) If necessary,

combine information from two independent serological tests (employing different antigens

and/or test principles). 3) If possible, re-evaluate samples generating a positive ELISA result

with IIFT on virus-infected cells (when evaluated by experienced personnel, the obtained

staining pattern contains additional information about signal specificity) and/or neutralization

testing.

Further studies will be necessary to assess sensitivity of the commercially available assays

in detecting anti-SARS-CoV2 IgG antibodies induced by SARS-CoV-2 infection in African

COVID-19 patients and to thoroughly identify causes for the reduced assay specificity in sera

from African donors.

ACKNOWLEDGMENTS

The authors thank J. Blessmann and S. Kann for providing symptom-free donor serum

samples from Lao PDR and Colombia, respectively. We thank C. Ehmen and N. Pekarek for

expert technical assistance.

FUNDING

The study was conducted within the framework of the project "East African Community (EAC)

regional network of public health reference laboratories for communicable diseases"

(https://mobilelabs.eac.int/) funded by the Federal Republic of Germany through the German

Development Bank (KfW). The study was supported by the German Research Foundation

(DFG, GU 883/4-1 and GU 883/5-1), by the German Federal Ministry of Health through

support of the WHO Collaborating Centre for Arboviruses and Hemorrhagic Fever Viruses at

BNITM (agreement ZMV I1-2517WHO005), through the Global Health Protection Program

(agreement ZMV I1-2517GHP-704), and through the COVID support agreement ZMVI1-

2520COR001. The funders had no role in study design, data collection and analysis,

decision to publish, or preparation of the manuscript.

AUTHOR BIOGRAPHY

Dr. Emmerich is a laboratory group leader at the Bernhard Nocht Institute for Tropical

Medicine in Hamburg, Germany. Her research is focused on diagnostics of viral infectious

diseases.

REFERENCES

1. WHO, COVID situation report 209, August 16th 2020.

2. FIND, https://www.finddx.org/covid-19/sarscov2-eval-immuno/, as accessed on September 14th 2020.

3. Johns Hopkins University, https://www.centerforhealthsecurity.org/resources/COVID-19/serology/Serology-based-tests-for-COVID-19.html, as accessed on September 14th 2020.

4. Geurts van Kessel CH, Okba NMA, Igloi Z, Bogers S, Embregts CWE, Laksono BM, *et al.* An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nature communications. 2020;11(1):3436.

5. Kruttgen A, Cornelissen CG, Dreher M, Hornef M, Imohl M, Kleines M. Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG. Journal of Clinical Virology. 2020;128:104394.

6. Theel ES, Harring J, Hilgart H, Granger D. Performance characteristics of four high-throughput immunoassays for detection of IgG antibodies against SARS-CoV-2. Journal of Clinical Microbiology. 2020; 58(8):e01243-20.

7. Weidner L, Gansdorfer S, Unterweger S, Weseslindtner L, Drexler C, Farcet M, *et al.* Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays. Journal of Clinical Virology. 2020;129:104540.

8. Pflüger LS, Bannasch JH, Brehm TT, Pfefferle S, Hoffmann A, Nörz D, van der Meirschen M, *et al.* Clinical evaluation of five different automated SARS-CoV-2 serology assays in a cohort of hospitalized COVID-19 patients. Journal of Clinical Virology. 2020; 130:104549.

9. Silveira ELV, Dominguez MR, Soares IS. To B or Not to B: Understanding B Cell Responses in the Development of Malaria Infection. Frontiers in immunology. 2018;9:2961.

10.   Van Esbroeck M, Meersman K, Michiels J, Arien KK, Van den Bossche D. Letter to

the editor: Specificity of Zika virus ELISA: interference with malaria. Euro surveillance.

2016;21(21).

11.   Reisinger EC, von Possel R, Warnke P, Geerdes-Fenge HF, Hemmer CJ, Pfefferle S,

et al. Screening of mothers in a COVID-19 low-prevalence region: Determination of

SARS-CoV-2 antibodies in 401 mothers from Rostock by ELISA and confirmation by

immunofluorescence. Deutsche Medizinische Wochenschrift. 2020; 145(17):e96-

e100.

12.   WHO, World malaria report. 2019.

TABLES

Table 1. SARS-CoV-2 IgG ELISA specificities

				Euroimmun Anti-SARS-CoV-2-NCP-ELISA IgG			Euroimmun Anti-SARS-CoV-2-ELISA IgG			*EDI*[TM] Novel Coronavirus COVID-19 IgG ELISA kit			Mikrogen *recom*Well SARS-CoV-2 IgG		
Ghana (n=79)	pos	bl	neg	9	3	67	7	3	69	16	9	54	5	2	72
	specificity (95% CI)			88.6 (79.5 – 94.1)			91.1 (82.6 – 95.9)			79.7 (69.5 – 87.2)			93.7 (85.7 – 97.6)		
Madagascar (n=79)	pos	bl	neg	0	1	78	0	0	79	3	2	74	1	1	77
	specificity (95% CI)			100.0 (94.4 – 100.0)			100.0 (94.4 – 100.0)			96.2 (89.0 – 99.1)			98.7 (92.5 – 100.0)		
Nigeria (n=40)	pos	bl	neg	11	5	24	3	4	33	15	6	19	4	1	35
	specificity (95% CI)			72.5 (57.0 – 84.0)			92.5 (79.4 – 98.1)			62.5 (47.0 – 75.8)			90.0 (76.4 – 96.6)		
Africa, all (n=198)	pos	bl	neg	20	9	169	10	7	181	34	17	147	10	4	184
	specificity (95% CI)			89.9 (84.8 – 93.4)			94.9 (90.8 – 97.3)			82.8 (76.9 – 87.5)			94.9 (90.8 – 97.3)		
Colombia (n=40)	pos	bl	neg	0	1	39	2	0	38	0	2	38	1	0	39
	specificity (95% CI)			100.0 (89.6 – 100.0)			95.0 (82.6 – 99.5)			100.0 (89.6 – 100.0)			97.5 (86.0 – 100.0)		
Lao PDR (n=20)	pos	bl	neg	0	0	20	0	0	20	0	0	20	0	1	19
	specificity (95% CI)			100.0 (81. 0 -100.0)			100.0 (81. 0 -100.0)			100.0 (81. 0 -100.0)			100.0 (81. 0 -100.0)		
Germany (n=75)	pos	bl	neg	0	2	73	0	0	75	2	1	72	3	0	72
	specificity (95% CI)			100.0 (94.2 – 100.0)			100.0 (94.2 – 100.0)			97.3 (90.2 – 99.8)			96.0 (88.4 – 99.1)		

191 pos/bl/neg: number of samples rated as positive (pos), borderline (bl), and negative (neg) by the respective test. CI: confidence

192 interval. For calculation of specificities, both negative and borderline results were classified as "not positive".

196 **Table 2. Correlation of SARS-CoV-2 IgG ELISA test results**

		Euroimmun Anti-SARS-CoV-2-NCP-ELISA IgG vs.	
		EDI[TM] Novel Coronavirus COVID-19 IgG ELISA	Euroimmun Anti-SARS-CoV-2-ELISA IgG
Ghana (n=79)	agreement: n_{pos} (%), n_{neg} (%)	6 (7.6), 60 (75.9)	3 (3.8), 66 (83.5)
	combined specificity % (95% CI)	92.4 (84.1 – 96.8)	96.2 (89.0 – 99.1)
Madagascar (n=79)	agreement: n_{pos} (%), n_{neg} (%)	0 (0.0), 76 (96.2)	0 (0.0), 79 (100.0)
	combined specificity % (95% CI)	100.0 (94.4 – 100.0)	100.0 (94.4 – 100.0)
Nigeria (n=40)	agreement: n_{pos} (%), n_{neg} (%)	9 (22.5), 23 (57.5)	2 (5.0), 28 (70.0)
	combined specificity % (95% CI)	77.5 (62.2 – 87.9)	95.0 (82.6 – 99.5)
Africa, all (n = 198)	agreement: n_{pos} (%), n_{neg} (%)	15 (7.6), 159 (80.3)	5 (2.5), 173 (87.4)
	combined specificity % (95% CI)	92.4 (87.8 – 95.4)	97.5 (94.1 – 99.1)

198 Both negative and borderline results were classified as "not positive"; n_{pos} : number of samples rated as positive by both assays;

199 n_{neg} : number of samples rated as "not positive" by both assays; CI: confidence interval.

    FIGURE LEGENDS

Figure 1. SARS-CoV-2 IgG ELISA results. Index values obtained for serum/plasma

samples collected before 2019 in three different African countries (Ghana (n=79),

Madagascar (n=79), Nigeria (n=40)), Colombia (n=40), Lao PDR (n=20), and Germany

(n=75) with **(A)** the Euroimmun Anti-SARS-CoV-2-NCP IgG ELISA, **(B)** the Euroimmun Anti-

SARS-CoV-2 IgG ELISA, **(C)** the EDI Novel Coronavirus COVID-19 IgG ELISA, and **(D)** the

Mikrogen *recom*Well SARS-CoV-2 IgG ELISA. Dotted lines represent negative and positive

cut-off values, respectively. Grey shading indicates index values rated as "borderline"

according to the manufacturers' instructions. Diamonds represent index values obtained for

two IgG positive COVID-19 patient sera sampled on day 19 post onset of symptoms (dark

grey: SARS-CoV-2 IgG IIFT titer 1:640, light grey: SARS-CoV-2 IgG IIFT titer 1:160) and one

negative control serum; error bars represent standard deviation of n=5 independent

measurements.

Figure 2. Correlation of SARS-CoV-2 IgG ELISA results. Index values obtained for the

Ghanaian (**A, B**), Madagascan (**C, D**), and Nigerian (**E, F**) serum samples with the

Euroimmun Anti-SARS-CoV-2-NCP IgG ELISA and the nucleoprotein-based EDI Novel

Coronavirus COVID-19 IgG ELISA **(A, C, E)** or the spike-based Euroimmun Anti-SARS-CoV-

2 IgG ELISA **(B, D, F)**. Dotted lines represent negative and positive cut-off values,

respectively. Grey shading indicates index values rated as "borderline" according to the

manufacturers' instructions.

Figure 1

Figure 2